ESTRO 2022 - Abstract Book

S740

Abstract book

ESTRO 2022

Conclusion GTV was defined differently with different imaging modalities and a mismatch with the pathological tumor volume was observed in thirteen of the fourteen included patients. For all patients, 5mm margin appears sufficient to ensure that all of the pathological information will be included during treatment.

PD-0822 Impact of radiotherapy laterality on patient-reported outcomes in T1-2 HPV tonsillar carcinoma

L. McDowell 1,2 , D. Rischin 3,2 , M. King 4 , L. Kenny 5,6 , S. Porceddu 6,7 , C. Wratten 8 , A. Macann 9 , J. Jackson 10 , M. Bressel 11 , T. Fua 1 , C. Lin 5 , C. Liu 1 , J. Corry 12,13 1 Peter MacCallum Cancer Centre, Department of Radiation Oncology, Melbourne, Australia; 2 University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, Australia; 3 Peter MacCallum Cancer Centre, Department of Medical Oncology, Melbourne, Australia; 4 University of Sydney, Sydney Quality of Life Office, Sydney, Australia; 5 Royal Brisbane and Women's Hospital, Department of Radiation Oncology, Brisbane, Australia; 6 University of Queensland, Faculty of Medicine, Brisbane, Australia; 7 Princess Alexandra Hospital, Department of Radiation Oncology, Brisbane, Australia; 8 Calvary Mater Hospital and University of Newcastle, Department of Radiation Oncology, Newcastle, Australia; 9 Auckland City Hospital and University of Auckland, Department of Radiation Oncology, Auckland, New Zealand; 10 Gold Coast Hospital, Icon Cancer Centre, Gold Coast, Australia; 11 Peter MacCallum Cancer Centre, Centre for Biostatistics and Clinical Trials, Melbourne, Australia; 12 GenesisCare, GenesisCare St Vincent's Hospital, Melbourne, Australia; 13 University of Melbourne, Department of Medicine, Melbourne, Australia Purpose or Objective There has been limited patient-reported outcome (PRO) data quantifying differences in risk-comparable patients based on receipt of unilateral radiotherapy (URT) and bilateral radiotherapy (BRT). The aim of this TROG 12.01 substudy was to report longitudinal variations in PROs based on radiotherapy (RT) laterality. Materials and Methods TROG 12.01 was a multicentre study conducted in Australia and New Zealand randomizing low-risk AJCC7 stage III/IV HPV- associated oropharyngeal cancer patients (HPV+ OPC) to RT (70Gy/35#) with weekly cisplatin or cetuximab. This substudy included patients with lateralized T1-2 N1-2b tonsillar cancer. PROs were collected at multiple timepoints and included: HNC symptom burden – MDASI-HN, quality of life – FACT-H&N and emotional distress – HADS.